Inhibition of anthrax lethal factor: Lability of hydroxamate as a chelating group

Applied Microbiology and Biotechnology

Volumn 94, Issue 4, 2012, Pages 1041-1049

  Li, Feng ^a,b,e   Chvyrkova, Irina ^a   Terzyan, Simon ^a   Wakeham, Nancy ^a   Turner, Robert ^c   Ghosh, Arun K ^d   Zhang, Xuejun C ^a   Tang, Jordan ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b OKLAHOMA CITY UNIVERSITY   (United States)

^c CoMentis Inc ^*  (United States)

^d PURDUE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Anthrax; Hydroxamate; Inhibitor; Lethal toxin; Metalloprotease

Indexed keywords

ANTHRAX; HYDROXAMATE; INHIBITOR; LETHAL TOXIN; METALLO-PROTEASE;

DISEASES; HYDROLYSIS; MACROPHAGES; ORGANIC ACIDS; TOXICITY;

CHELATION;

ANTHRAX TOXIN; CHELATING AGENT; ENZYME INHIBITOR; HYDROXAMIC ACID DERIVATIVE; METALLOPROTEINASE; ZINC;

BACTERIUM; BIOASSAY; CHELATING AGENT; ENZYME ACTIVITY; INFECTIVITY; INHIBITION; INHIBITOR; ORGANIC ACID; PEPTIDE; POLLUTANT SOURCE; TOXICITY; TOXIN;

ANIMAL CELL; ANTHRAX; ARTICLE; CELL PROTECTION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; LETHAL GENE; LYSIS; MACROPHAGE; MOUSE; NONHUMAN;

ANIMALS; ANTIGENS, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; CELLS, CULTURED; CHELATING AGENTS; HYDROXAMIC ACIDS; KINETICS; MACROPHAGES; MICE; PEPTIDES; PROTEASE INHIBITORS;

BACILLUS ANTHRACIS; MURINAE;

EID: 84862880805     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-012-3893-7     Document Type: Article

References (25)

1. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M,Montecucco C (2002) Anthrax toxin: a tripartite lethal combination. FEBS Lett 531(3):384-388
2. Brown DA, Fitzpatrick NJ, Muller-Bunz H, Ryan AT (2006) Di-, tri-, and tetranuclear zinc hydroxamate complexes as structural models for the inhibition of zinc hydrolases by hydroxamic acids. Inorg Chem 45(11):4497-4507
3. Chvyrkova I, Zhang XC, Terzyan S (2007) Lethal factor of anthrax toxin binds monomeric form of protective antigen. Biochem Biophys Res Comm 360(3):690-695
4. Ermolieff J, Loy JA, Koelsch G, Tang J (2000) Proteolytic activation of recombinant pro-memapsin 2 (pro-β-secretase) studied with new fluorogenic substrate. Biochemistry 39(40):12450-12456
5. Goldman ME, Cregar L, Nguyen D, Simo O, O'Malley S, Humphreys T (2006) Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol. doi:10.1186/1471-2210-6-8
6. Hanna P (1999) Lethal toxin actions and their consequences. J Appl Microbiol 87(2):285-287
7. Jacobsen FE, Lewis JA, Cohen SM (2007) The design of inhibitors for medicinally relevant metalloproteins. Chem Med Chem 2 (2):152-171
8. Kacprzak MM, Peinado JR, Than ME, Appel J, Henrich S, Lipkind G, Houghten RA, Bode W, Lindberg I (2004) Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem 279(35):36788-36794
9. Li F, Terzyan S, Tang J (2011) Subsite specificity of anthrax lethal factor and its implications for inhibitor development. Biochem Biophys Res Commun 407(2):400-405
10. Li Y, Sherer K, Cui X, Eichacher PQ (2007) New insight into the pathogenesis and treatment of anthrax toxin-induced shock. Expert Opin Biol Ther 7(6):843-854
11. Moayeri M, Martinez NW, Wiggins J, Young HA, Leppla SH (2004) Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophages sensitivity. Infect Immun 72(8):4439-4447
12. Mourez M (2004) Anthrax toxins. Rev Physiol Biochem Pharmaco 152:135-164
13. Panchal RG, Hermone AR, Nguyen TL, Wong TY, Schmidt J, Lane D, McGrath C, Turk BE, Burnett J, Aman MJ, Little S, Sausville EA, Zaharevitz DW, Cantley LC, Liddington RC, Gussio R, Bavari S (2004) Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 11(1):67-72
14. Paniffer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, Bienkowska J, Lacy DB, Collier RJ, Park S, Leppla SH, Hanna P, Liddington RC (2001) Crystal structure of the anthrax lethal factor. Nature 414(6860):229-233
15. Peinado JR, Kacprzak MM, Leppla SH, Lindberg I (2004) Crossinhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 321(3):601-605
16. Rainey GJ, Young JA (2004) Antitoxins: novel strategies to target agents of bioterrorism. Nat Rev Microbiol 2(9):721-726
17. Schepetkin IA, Khlebnikov AI, Kirpotina LN, Quinn MT (2006) Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem 49(17):5232-5244
18. Tonello F, Seveso M, Marin O,Mock M, Montecucco C (2002) Screening inhibitors of anthrax lethal factor. Nature 418(6896):386
19. Turk BE, Wong TY, Schwarzenbacher R, Jarrell ET, Leppla SH, Collier RJ, Liddington RC, Cantley LC (2004) The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Naure Struct Mol Biol 11(1):60-66
20. Turk BE (2007) Manipulation of host signaling pathways by anthrax toxins. Biochem J 402(3):405-417
21. Turk BE (2008) Discovery and development of anthrax lethal factor metalloproteinase inhibitors. Curr Pharm Biotechno 9(1):24-33
22. Turner RT, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh AK, Tang J (2001) Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40(34):10001-10006
23. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C (2000) Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J 352:739-745
24. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. P Natl Acad Sci 97(24):13003-13008
25. Yong JA, Collier RJ (2007) Anthrax toxin: receptor binding, internalization, pore formation and translocation. Annu Rev Biochem 76:243-265